CommercialAdministrativeLow impact
08.01.35k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Summary
This is a reissue of an existing policy for Rylaze (asparaginase Erwinia chrysanthemi) with an effective date of April 29, 2026. The policy content appears to be administrative in nature, updating the commercial policy documentation for this specialized cancer medication used when patients develop allergies to standard asparaginase treatments.
Action Required
By April 29, 2026: Review updated policy for Rylaze (asparaginase Erwinia chrysanthemi) at the provided URL to understand any changes to coverage criteria or billing requirements. This primarily affects oncology practices treating patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.